Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

287 trials

NCT06571669
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
Not applicable · United States · 19 sites
Registry update: 6 Aug 2026
NCT06754891
Recruiting
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Phase 1 · China · 30 sites
Registry update: 12 May 2026
NCT06758024
Recruiting
PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease
Not applicable · Chile · 1 site
Registry update: 28 Feb 2025
NCT06100289
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Phase 3 · Belgium, Bulgaria, Switzerland, Denmark, Spain, Ireland, Italy, Japan, South Korea, Netherlands, Poland, Portugal, Romania, Serbia, Taiwan, United States · 57 sites
Registry update: 3 Aug 2026
NCT07644117
Recruiting
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease
Not applicable · Israel · 1 site
Registry update: 12 Jun 2026
NCT06995170
Recruiting
Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With Inflammatory Bowel Disease Progression
Not applicable · China · 1 site
Registry update: 29 May 2025
NCT06655415
Recruiting
Family Members at INcreased-risk for Developing Inflammatory Bowel Disease
Not applicable · United States · 1 site
Registry update: 7 Oct 2026
NCT06636656
Recruiting
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
Phase 2 · Belgium, Czechia, Poland, Serbia, Slovakia, United States · 41 sites
Registry update: 21 Aug 2026
NCT06698601
Recruiting
Wild Blueberries in Colitis
Not applicable · Germany · 1 site
Registry update: 1 Oct 2026
NCT06548399
Recruiting
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease
Not applicable · Canada · 1 site
Registry update: 1 Oct 2026
NCT06651281
Recruiting
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Phase 3 · Czechia, France, United Kingdom, Georgia, Hungary, Poland, United States · 37 sites
Registry update: 3 Nov 2026
NCT06516237
Recruiting
Development of Novel Imaging and Molecular Biomarkers of Fibrosis in Patient With Ulcerative Colitis
Not applicable · Italy · 1 site
Registry update: 15 Jan 2026
NCT06696222
Recruiting
Fermented Vegan Optimized Diet in Health and Colitis
Not applicable · Sweden · 1 site
Registry update: 21 Aug 2026
NCT06606808
Recruiting
Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Phase 1/2 · Netherlands · 1 site
Registry update: 5 Mar 2025
NCT06709209
Recruiting
AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis
Not applicable · Belgium, Germany, Ireland, Italy, Japan, Singapore · 11 sites
Registry update: 3 Dec 2024
NCT06663332
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Phase 3 · Argentina, Australia, Belgium, Brazil, China, Germany, Spain, France, United Kingdom, Israel, Italy, Japan, South Korea, Norway, Poland, Portugal, United States · 58 sites
Registry update: 3 Nov 2026
NCT06550310
Recruiting
Nutrition and Clinical Outcomes in IBD
Not applicable · United Kingdom · 1 site
Registry update: 19 Feb 2026
NCT07347834
Recruiting
TRIOCOL - The Study of Continued Advanced Medical Therapy or Colectomy in Patients With Ulcerative Colitis
Not applicable · Sweden · 1 site
Registry update: 21 Jan 2026
NCT06619990
Recruiting
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Phase 1/2 · Argentina, Australia, Bulgaria, Brazil, Canada, Chile, Spain, Georgia, Greece, Croatia, Hungary, Jordan, Lebanon, Moldova, Poland, Portugal, Romania, Ukraine, United States · 94 sites
Registry update: 30 Oct 2026
2023-509775-16-00
Recruiting
This is a multicenter, double-blind, randomized study to compare the safety, effectiveness and immunogenicity (level and body resistance to drugs) of two biological drugs administered intravenously - vedolizumab (a drug not registered in pediatric patients) and infliximab (used as standard therapy) in pediatric patients with ulcerative colitis aged 6-17 years.
Phase 2 · Poland · 10 sites
Registry update: 20 Dec 2024

Ordered by registry start date. Freshness and sponsorship never change the order.